Losartan and kidney protection
Pro Research Analysisby 
Searched over 200M research papers
Losartan and Kidney Protection: Mechanisms and Clinical Evidence
Losartan and Chronic Kidney Disease (CKD) Protection
Losartan, an angiotensin II receptor blocker (ARB), has shown significant kidney-protective effects in various models of chronic kidney disease. In normotensive patients with nondiabetic stage 3 CKD, daily losartan (50 mg) significantly reduced proteinuria and stabilized kidney function over 12 months, without affecting blood pressure or causing major side effects. This suggests losartan can slow CKD progression even in patients without high blood pressure, making it a safe and effective option for kidney protection in this population .
Losartan in Diabetic Nephropathy
In diabetic nephropathy models, losartan delivered via optimized nano-bilosomes improved its oral bioavailability and enhanced its protective effects. This formulation reduced blood urea nitrogen, proteinuria, and inflammatory cytokines more effectively than the free drug. It also preserved kidney structure and reduced inflammation and fibrosis, highlighting its potential for mitigating diabetes-induced kidney damage .
Protection Against Acute Kidney Injury (AKI) and Ischemia/Reperfusion Injury
Losartan has demonstrated protective effects in acute kidney injury, particularly following ischemia/reperfusion (I/R) events. Studies in rats show that losartan reduces kidney damage, lowers serum urea and creatinine, and decreases cell death after I/R injury. It also modulates the expression of circular RNAs involved in cell survival pathways, further supporting its role in reducing AKI severity 410. Additionally, losartan reduced the progression to chronic kidney disease and mortality after AKI in animal models, an effect not matched by other blood pressure-lowering drugs like hydralazine, indicating a specific benefit related to angiotensin II receptor blockade .
Losartan and Drug-Induced Nephrotoxicity
Losartan protects against nephrotoxicity caused by drugs such as cisplatin, a common chemotherapy agent. It reduces kidney injury by restoring normal levels of kidney function markers, decreasing oxidative stress, and suppressing cell death (apoptosis) while promoting tubular regeneration. These effects have been observed in both rat and mouse models, supporting the use of losartan as a nephroprotective agent during cisplatin therapy 37.
Mechanisms of Renal Protection: Anti-Inflammatory and Anti-Fibrotic Effects
Losartan’s kidney-protective effects are linked to several mechanisms:
- Reduction of Glomerular Hypertension and Proteinuria: Losartan lowers glomerular capillary pressure and protein leakage, which are key contributors to kidney damage in chronic allograft injury and hypertension models .
- Anti-Inflammatory Action: It suppresses the recruitment of inflammatory cells (macrophages and T-cells) and the expression of cytokines and chemokines that drive kidney inflammation and fibrosis 68.
- Modulation of Renal Renin-Angiotensin System (RAS): Losartan helps balance pro- and anti-angiogenic factors, preserving kidney microvasculature and reducing tissue injury, especially in conditions like chronic intermittent hypoxia .
- Activation of Protective Pathways: In hypertensive models, losartan activates the PRCP-kallikrein axis and reduces TGF-beta1 expression, both of which contribute to reduced fibrosis and improved kidney structure .
Conclusion
Losartan provides robust kidney protection across a range of conditions, including chronic kidney disease, diabetic nephropathy, acute kidney injury, and drug-induced nephrotoxicity. Its benefits stem from reducing proteinuria, inflammation, oxidative stress, and fibrosis, as well as preserving kidney structure and function. These effects are observed even at moderate doses and in patients without high blood pressure, making losartan a valuable therapeutic option for kidney protection in diverse clinical settings 1234+6 MORE.
Sources and full results
Most relevant research papers on this topic